Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Cidara Therapeutics (CDTX) over the last 6 years, with Sep 2025 value amounting to -$176.5 million.

  • Cidara Therapeutics' Cash from Investing Activities fell 166381.13% to -$176.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.4 million, marking a year-over-year decrease of 40642.26%. This contributed to the annual value of -$129,000 for FY2024, which is 74.46% up from last year.
  • Per Cidara Therapeutics' latest filing, its Cash from Investing Activities stood at -$176.5 million for Q3 2025, which was down 95,489.19% from $185,000 recorded in Q1 2025.
  • In the past 5 years, Cidara Therapeutics' Cash from Investing Activities registered a high of $185,000 during Q1 2025, and its lowest value of -$176.5 million during Q3 2025.
  • For the 3-year period, Cidara Therapeutics' Cash from Investing Activities averaged around -$22.1 million, with its median value being -$106,500 (2023).
  • The largest annual percentage gain for Cidara Therapeutics' Cash from Investing Activities in the last 5 years was 904.35% (2025), contrasted with its biggest fall of 166,381.13% (2025).
  • Over the past 5 years, Cidara Therapeutics' Cash from Investing Activities (Quarterly) stood at -$12,000 in 2021, then grew by 25.00% to -$9,000 in 2022, then tumbled by 1,877.78% to -$178,000 in 2023, then rose by 15.87% to -$106,000 in 2024, then slumped by 166,381.13% to -$176.5 million in 2025.
  • Its last three reported values are -$176.5 million in Q3 2025, $185,000 for Q1 2025, and -$106,000 during Q3 2024.